Kerri Glassner, DO

Assistant Professor of Clinical Medicine, Academic Institute
Houston Methodist
Weill Cornell Medical College


Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
Saleh, A, Ansari, U, Abughazaleh, S, Glassner, K & Abraham, BP 2022, , Biologics: Targets and Therapy, vol. 16, pp. 67-83.

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Alayo, QA, Fenster, M, Altayar, O, Glassner, KL, Llano, E, Clark-Snustad, K, Patel, A, Kwapisz, L, Yarur, AJ, Cohen, BL, Ciorba, MA, Thomas, D, Lee, SD, Loftus, EV, Fudman, DI, Abraham, BP, Colombel, JF & Deepak, P 2022, , Crohns and Colitis 360, vol. 4, no. 1, otac002.

Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis
Abraham, B & Glassner, K 2021, , Current opinion in gastroenterology, vol. 37, no. 4, pp. 344-350.

Risk factors for and frequency of ct scans, steroid use, and repeat visits in inflammatory bowel disease patients seen at a single-center emergency department: A retrospective cohort study
Euers, L, Abughazaleh, S, Glassner, K, Gajula, P, Jones-Pauley, M, Ezeana, C, Puppala, M, Wang, L, Wong, S, Oglat, A, Nickerson, S & Abraham, BP 2021, , Journal of Clinical Medicine, vol. 10, no. 12, 2679.

Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease
Agrawal, T, Acquah, I, Dey, AK, Glassner, K, Abraham, B, Blankstein, R, Virani, SS, Blaha, MJ, Valero-Elizondo, J, Mehta, N, Quigley, EM, Cainzos-Achirica, M & Nasir, K 2021, , American journal of preventive cardiology, vol. 6, pp. 100171.

Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week
Cainzos-Achirica, M, Glassner, K, Zawahir, HS, Dey, AK, Agrawal, T, Quigley, EMM, Abraham, BP, Acquah, I, Yahya, T, Mehta, NN & Nasir, K 2020, , Journal of the American College of Cardiology, vol. 76, no. 24, pp. 2895-2905.

The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Glassner, K, Oglat, A, Duran, A, Koduru, P, Perry, C, Wilhite, A & Abraham, BP 2020, , Journal of Digestive Diseases, vol. 21, no. 5, pp. 264-271.

The microbiome and inflammatory bowel disease
Glassner, KL, Abraham, BP & Quigley, EMM 2020, , Journal of Allergy and Clinical Immunology, vol. 145, no. 1, pp. 16-27.

The use of vedolizumab in pregnancy and breastfeeding in women with inflammatory bowel disease
Glassner, K & Abraham, BP 2019, , Practical Gastroenterology, vol. 43, no. 9, pp. 13-18.

Autoimmune liver disease and the enteric microbiome
Glassner, K, Quigley, EMM, Franco, L & Victor, DW 2018, , AIMS Microbiology, vol. 4, no. 2, pp. 334-346.